<?xml version="1.0" encoding="UTF-8"?>
<p>Temozolomide‐based chemotherapy is one of the most frequently used second‐line treatments for unresectable EPNEC.
 <xref rid="cas14811-bib-0008" ref-type="ref">
  <sup>8</sup>
 </xref> The activity of TMZ in patients with unresectable EPNEC has been evaluated in several trials; however, most of them were retrospective studies or the study target was not limited to EPNEC.
 <xref rid="cas14811-bib-0015" ref-type="ref">
  <sup>15</sup>
 </xref>, 
 <xref rid="cas14811-bib-0016" ref-type="ref">
  <sup>16</sup>
 </xref> Thus, the activity of TMZ for advanced EPNEC is still unclear. Moreover, there is no evidence of the efficacy of TMZ for Japanese patients with advanced EPNEC because TMZ is not yet approved in the Japanese health insurance system for use in advanced EPNEC. Prospective clinical study of TMZ monotherapy in Japanese patients with advanced EPNEC is a worthy challenge.
</p>
